---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-067474"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-05-28T20:05:29+00:00"
generated_at: "2026-05-28T21:19:07.342665+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BrainStorm appoints former FDA official Peter Pitts to Board ahead of ALS trial

## Summary
- Appointed Peter Pitts, former FDA Associate Commissioner, to the Board effective May 25, 2026.
- Pitts granted option for 150,000 shares; half vested immediately, half vest in six months.
- Company preparing to initiate Phase 3b ENDURANCE trial for NurOwn in ALS under FDA Special Protocol Assessment.
- Board expanded from seven to eight directors; Pitts determined independent under SEC rules.

## SEC filing metadata
- accession: 0001104659-26-067474
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-05-28T20:05:29+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926067474/0001104659-26-067474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926067474/tm2615772d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-067474
- JSON: https://secwatch.observer/filing/0001104659-26-067474.json
- Plain text: https://secwatch.observer/filing/0001104659-26-067474.txt

## Source-grounded claims
- claim_id: ccef899f81
  claim: Peter Pitts was appointed as Director at BRAINSTORM CELL THERAPEUTICS INC..
  evidence_excerpt: appointed Peter Pitts to serve as a director of the Company, effective as of the same day
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926067474/0001104659-26-067474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.